Randomized, multicentre, comparative clinical evaluation of cefuroxime-sulbactam versus amoxicillin-clavulanic acid therapy in the treatment of lower respiratory tract infections

Journal of International Medical Research

Volumn 36, Issue 6, 2008, Pages 1293-1304

  Pareek, Anil ^a   Pednekar, S ^b   Prasad, H B ^c   Salagre, S ^d   Chandurkar, N ^a  

^a Ipca Laboratories Ltd   (India)

^b BYL NAIR CHARITABLE HOSPITAL   (India)

^c B J MEDICAL COLLEGE   (India)

^d KEM HOSPITAL   (India)

Author keywords

Amoxicillin clavulanic acid; Cefuroxime sulbactam; Co amoxiclav; Community acquired pneumonia; Lower respiratory tract infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFUROXIME; SULBACTAM; AMOXICILLIN; ANTIINFECTIVE AGENT; CLAVULANIC ACID;

ACINETOBACTER; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPONATREMIA; KLEBSIELLA PNEUMONIAE; LOOSE FECES; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; UNCONSCIOUSNESS; UNSPECIFIED SIDE EFFECT; VOMITING; ADOLESCENT; COMPARATIVE STUDY; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CEFUROXIME; CLAVULANIC ACID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RESPIRATORY TRACT INFECTIONS; SULBACTAM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 59649129580     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600617     Document Type: Article

References (19)

1. Dixon RE: Economic costs of respiratory tract infections in the United States. Am J Med 1985; 78: 45-51.
2. Glover ML, Reed MD: Lower respiratory tract infections. In: Pharmacotherapy A Pathophysiologic Approach (DiPiro JT, Talbert RL, Yee GC, et al, eds) 6th edn. New York: McGrawHill, 2005; pp 1943-1962.
3. Ortqvist A: Treatment of community-acquired lower respiratory tract infections in adults. Eur Respir J Suppl 2002; 36: 40s-53s.
4. Fass RJ: Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective. J Antimicrob Chemother 1993; 32 (suppl A): 17-27.
5. Klein M: Multicenter trial of cefpodoxime proxetil vs. amoxicillin-clavulanate in acute lower respiratory tract infections in childhood. International Study Group. Pediatric Infect Dis J 1995; 14(4 suppl): S19-S22.
6. Ambrose PG, Quintilian R, Nightingale CH, et al: Continous vs. intermittent infusion of cefuroxime for the treatment of community acquired pneumonia. Infect Dis Clin Pract 1998; 7: 463-470.
7. Spencer RC, Griggs JV, Brown GW: A dose-ranging study of cefuroxime axetil in the treatment of lower respiratory tract infections in general practice. Drugs Exp Clin Res 1987; 13: 101-103.
8. Samantha TC, Bax RP, Pearson RM, et al: Clinical study of cefuroxime in the treatment of lower respiratory tract infections. Curr Med Res Opin 1980; 6: 466-471.
9. Marks WA, Stutman HR, Marks MI, et al: Cefuroxime versus ampicillin plus chloramphenicol in childhood bacterial meningitis: a multicenter randomized controlled trial. J Pediatr 1986; 109: 123-130.
10. Bush K: New β-lactamase in Gram-negative bacteria: diversity and impact on selection of antimicrobial therapy. Clin Infect Dis 2001; 32: 1085-1089.
11. Virk A, Steckelberg JM: Clinical aspects of antimicrobial resistance. Mayo Clin Proc 2000; 75: 200-214.
12. Mangiarotti P, Manara G, Grassi G, et al: Activity of an ampicillin/sulbactam combination in respiratory infections. G Ital Chemiotr 1989; 36: 39-44 [in Italian, English abstract].
13. Lee N, Yuen KY, Kumana CR: Clinical role of beta-lactam/beta-lactamase inhibitor combinations. Drugs 2003; 63: 1511-1524.
14. Zhang YL, Li JT: The in vitro activity of sulbactam combined with third generation cephalosporins against third generation cephalosporin-resistant bacteria. Int J Antimicrob Agents 2001; 17: 143-146.
15. British Medical Association and Royal Pharmaceutical Society of Great Britain: British National Formulary, 55th edn. London: BMJ Group and RPS Publishing, March 2008; p 289.
16. Physicians' Desk Reference®, 62nd edn. New York: Thomson Healthcare, 2008; p 1643.
17. Mayhew SR: A comparison of cefuroxime axetil and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infection in the general practice. In: The Management of Lower Respiratory Tract Infections with Cefuroxime Axetil (Emmersion AM, ed). Royal Society of Medicine Services International Congress and Symposium Series. London Royal Society of Medicine Services, 1987; vol 124: pp 45-52.
18. Schnelle K: Comparative randomised clinical trial of cefuroxime axetil (CAE) vs. amoxicillin + clavulanic acid (AMC) in patients with acute exacerbations of chronic bronchitis (CB). In: Selected Abstracts Presented at the Eighth Mediterranean Congress of Chemotherapy Athens, Greece 1992. Greenford: Glaxo, 1992; abstract 9.
19. Geckler RW: A comparison of ampicillin/sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract. Clin Ther 1994; 16: 662-672.